Literature DB >> 10632286

Clinical goals and performance measures for cholesterol management in secondary prevention of coronary heart disease.

T H Lee1, J I Cleeman, S M Grundy, C Gillett, R C Pasternak, J Seidman, C Sennett.   

Abstract

Guidelines from the National Cholesterol Education Program (NCEP) recommend reduction of low-density lipoprotein cholesterol (LDL-C) to 100 mg/dL (2.59 mmol/L) or less in patients with established coronary heart disease (CHD). However, the National Committee for Quality Assurance (NCQA) is implementing a new performance measure as part of the Health Plan Employer and Data Information Set (HEDIS) that appears to endorse a different target. The new HEDIS measure will require managed care organizations seeking NCQA accreditation to measure and report the percentage of patients who have had major CHD events who achieve LDL-C levels less than 130 mg/dL (3.36 mmol/L) between 60 and 365 days after discharge. These different LDL-C thresholds emphasize the difference between a clinical goal for the management of individual patients (< or =100 mg/dL) and a performance measure used to evaluate the care of a population of patients (<130 mg/dL). This article discusses the rationale for each threshold and explains the use of 2 different thresholds for these 2 purposes. Both the NCQA and NCEP expect that the new HEDIS measure will encourage managed care organizations to develop systems that improve secondary prevention of CHD.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10632286     DOI: 10.1001/jama.283.1.94

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  8 in total

Review 1.  Pharmacoeconomics of lipid-lowering drugs.

Authors:  Dean G Smith
Journal:  Curr Atheroscler Rep       Date:  2003-01       Impact factor: 5.113

Review 2.  In-hospital initiation of statin therapy in patients with acute coronary events.

Authors:  Gregg C Fonarow
Journal:  Curr Atheroscler Rep       Date:  2003-09       Impact factor: 5.113

3.  LDL-apheresis therapy.

Authors:  Patrick M Moriarty
Journal:  Curr Treat Options Cardiovasc Med       Date:  2006-08

4.  Use of cholesterol-lowering therapy and related beliefs among middle-aged adults after myocardial infarction.

Authors:  John Z Ayanian; Bruce E Landon; Mary Beth Landrum; James R Grana; Barbara J McNeil
Journal:  J Gen Intern Med       Date:  2002-02       Impact factor: 5.128

Review 5.  Statin therapy after acute myocardial infarction: are we adequately treating high-risk patients?

Authors:  Gregg C Fonarow
Journal:  Curr Atheroscler Rep       Date:  2002-03       Impact factor: 5.113

6.  Assessing appropriateness of lipid management among patients with diabetes mellitus: moving from target to treatment.

Authors:  Ashley J Beard; Timothy P Hofer; John R Downs; Michelle Lucatorto; Mandi L Klamerus; Rob Holleman; Eve A Kerr
Journal:  Circ Cardiovasc Qual Outcomes       Date:  2012-12-11

7.  Ambulatory hypercholesterolemia management in patients with atherosclerosis. Gender and race differences in processes and outcomes.

Authors:  Stephen D Persell; Saverio M Maviglia; David W Bates; John Z Ayanian
Journal:  J Gen Intern Med       Date:  2005-02       Impact factor: 5.128

8.  Association of serum total cholesterol and left ventricular ejection fraction in patients with heart failure caused by coronary heart disease.

Authors:  Yan Liu; Zirui Hao; Chun Xiao; Ling Liu; Huocheng Liao
Journal:  Arch Med Sci       Date:  2017-10-12       Impact factor: 3.318

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.